USA – Merck has released specific data for Keytruda in early-stage lung cancer, indicating an advantage over Roche’s first-to-market Tecentriq. Postsurgery use of Keytruda reduced the risk of disease recurrence…
Read MoreMerck details Keytruda’s post-surgery lung cancer win
